Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Artemisinins are a class of drugs used to treat malaria. They do not have a single, specific molecular target. Instead, they are activated by intraparasitic heme/iron(II) to generate free radicals. These free radicals non-selectively alkylate and damage a wide range of parasite proteins and membranes, disrupting essential parasitic processes and leading to cell death. While specific proteins like falcipains and PfATP6 have been proposed as potential targets, the primary mechanism involves promiscuous alkylation rather than selective binding.
Artemisinins are activated by heme/iron(II) within the parasite, generating free radicals that alkylate and damage multiple parasite proteins and membranes, leading to cell death.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Multiple Parasite Proteins and Membranes (Target of Artemisinins) (N/A).